Whole Gene Sequencing for Diagnosis Is Goal of Beth Israel Deaconess Medical Center and GenomeQuest in a New Collaboration
Goals are to use whole gene sequencing to develop better clinical laboratory assays in support of personalized medicine
Creating new clinical laboratory tests to support personalized medicine is one goal of a unique collaboration recently announced that involves the pathology department at Beth Israel Deaconess Medical Center (BIDMC) and GenomeQuest, Inc. (NASDAQ:GQ). The two collaborators are expanding a relationship launched several years ago that involved doing whole genome sequencing of tumors.
More specifically, the expanded relationship will be a two-year collaboration to develop whole-genome analysis (WGA) applications for personalized medicine. The move signals pathologists and clinical laboratory managers that first movers are taking steps to address the growing need for clinical genomics informatics infrastructure.
“The plummeting cost of sequencing and the increasing volume of predictive, public studies makes the clinical application of genomics not just a practicality but a healthcare imperative,” declared GenomeQuest CEO Richard Resnick. “We believe that our collaboration with a combined innovation and delivery leader like BIDMC is a major step forward in expanding genomics and its rewards from the bench to the bedside.” (more…)